NG
LGND icon

Norden Group’s Ligand Pharmaceuticals LGND Stock Holding History

Norden Group’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$251K Sell
1,259
-62
-5% -$12.3K 0.02% 515
2025
Q4 		$250K Sell
1,321
-774
-37% -$149K 0.02% 526
2025
Q3 		$371K Buy
+2,095
New +$311K 0.04% 414

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return

Norden Group's LGND Position: Q1 2026 in Review

Norden Group reduced its Ligand Pharmaceuticals (LGND) stake by 4.7% in Q1 2026, selling an estimated $12.3K and leaving 1,259 shares worth $251K. The position accounts for 0.02% of the portfolio, ranked #515.

Norden Group first reported a position in LGND in Q3 2025 and has held it in 3 quarters since. The position peaked at $371K in Q3 2025. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Norden Group held 1,259 shares of Ligand Pharmaceuticals worth $251K as of Q1 2026.
  • Norden Group sold 62 Ligand Pharmaceuticals shares in Q1 2026, an estimated $12.3K.
  • Ligand Pharmaceuticals made up 0.02% of Norden Group's portfolio in Q1 2026, its #515 holding.
  • Norden Group first reported a position in Ligand Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Norden Group's Ligand Pharmaceuticals position peaked at $371K in Q3 2025.
  • 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Norden Group's 13F filing for Q1 2026, filed 15 Apr 2026.